NCT06946199View on ClinicalTrials.gov

An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 30, 2025

Study Completion Date

November 30, 2026

Conditions
Rheumatoid Arthritis (RA)
Interventions
BIOLOGICAL

cizutamig

Cizutamig will be dosed according to the assigned group.

Trial Locations (1)

430000

Wuhan Union Hospital, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER